Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-044196
Filing Date
2024-10-30
Accepted
2024-10-30 07:53:31
Documents
64
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q itci-20240930.htm   iXBRL 10-Q 916901
2 EX-10.6 itci-20240930xex106.htm EX-10.6 23209
3 EX-10.7 itci-20240930xex107.htm EX-10.7 53403
4 EX-31.1 itci-20240930xex311.htm EX-31.1 9622
5 EX-31.2 itci-20240930xex312.htm EX-31.2 9635
6 EX-32 itci-20240930xex32.htm EX-32 5419
  Complete submission text file 0001628280-24-044196.txt   4941765

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT itci-20240930.xsd EX-101.SCH 32943
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT itci-20240930_cal.xml EX-101.CAL 60154
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT itci-20240930_def.xml EX-101.DEF 130555
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT itci-20240930_lab.xml EX-101.LAB 488210
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT itci-20240930_pre.xml EX-101.PRE 319217
67 EXTRACTED XBRL INSTANCE DOCUMENT itci-20240930_htm.xml XML 584897
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36274 | Film No.: 241407490
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)